Adults 18-75 years of age with symptoms, or a diagnosis, of atopic dermatitis for at least 3 years may qualify to participate. Individuals must have atopic dermatitis covering 10% or more of their body, with moderate to severe disease at the time of study entry. Participants must also have no prior exposure to biologic medication.
Eligible participants will receive the investigational medication (active drug), dupilumab (a monoclonal antibody used for allergic diseases), or a placebo (inactive substance). These substances will be administered orally and by injection. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided, along with an optional open label extension upon completion of the trial.
Study participation will last about 36 weeks and include about 16 visits to the study centre.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.